nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3B—prostate cancer	0.618	1	CbGaD
Lithium—GSK3A—penis—prostate cancer	0.0168	0.211	CbGeAlD
Lithium—IMPA2—prostate gland—prostate cancer	0.00471	0.0589	CbGeAlD
Lithium—GSK3B—prostate gland—prostate cancer	0.00462	0.0578	CbGeAlD
Lithium—IMPA1—renal system—prostate cancer	0.00428	0.0535	CbGeAlD
Lithium—GSK3A—prostate gland—prostate cancer	0.00402	0.0503	CbGeAlD
Lithium—IMPA2—seminal vesicle—prostate cancer	0.00399	0.0499	CbGeAlD
Lithium—GSK3A—seminal vesicle—prostate cancer	0.0034	0.0425	CbGeAlD
Lithium—GSK3B—epithelium—prostate cancer	0.0034	0.0425	CbGeAlD
Lithium—IMPA2—renal system—prostate cancer	0.00321	0.0402	CbGeAlD
Lithium—IMPA2—urethra—prostate cancer	0.00315	0.0395	CbGeAlD
Lithium—GSK3B—renal system—prostate cancer	0.00315	0.0394	CbGeAlD
Lithium—IMPA2—Teniposide—Etoposide—prostate cancer	0.00279	1	CbGdCrCtD
Lithium—IMPA1—testis—prostate cancer	0.00277	0.0346	CbGeAlD
Lithium—GSK3A—renal system—prostate cancer	0.00274	0.0343	CbGeAlD
Lithium—GSK3A—urethra—prostate cancer	0.00269	0.0337	CbGeAlD
Lithium—IMPA2—bone marrow—prostate cancer	0.00243	0.0304	CbGeAlD
Lithium—GRIA3—testis—prostate cancer	0.00235	0.0294	CbGeAlD
Lithium—IMPA2—testis—prostate cancer	0.00208	0.026	CbGeAlD
Lithium—GSK3A—bone marrow—prostate cancer	0.00207	0.0259	CbGeAlD
Lithium—GSK3B—testis—prostate cancer	0.00204	0.0255	CbGeAlD
Lithium—GSK3A—testis—prostate cancer	0.00177	0.0221	CbGeAlD
Lithium—IMPA2—lymph node—prostate cancer	0.0015	0.0188	CbGeAlD
Lithium—GSK3B—lymph node—prostate cancer	0.00148	0.0185	CbGeAlD
Lithium—GSK3A—lymph node—prostate cancer	0.00128	0.0161	CbGeAlD
Lithium—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	8.99e-05	0.000742	CcSEcCtD
Lithium—Loss of consciousness—Etoposide—prostate cancer	8.84e-05	0.000729	CcSEcCtD
Lithium—Lethargy—Doxorubicin—prostate cancer	8.84e-05	0.000729	CcSEcCtD
Lithium—Dizziness—Goserelin—prostate cancer	8.83e-05	0.000729	CcSEcCtD
Lithium—Ataxia—Epirubicin—prostate cancer	8.8e-05	0.000726	CcSEcCtD
Lithium—Somnolence—Mitoxantrone—prostate cancer	8.77e-05	0.000724	CcSEcCtD
Lithium—Dizziness—Conjugated Estrogens—prostate cancer	8.75e-05	0.000722	CcSEcCtD
Lithium—Feeling abnormal—Estradiol—prostate cancer	8.73e-05	0.00072	CcSEcCtD
Lithium—Convulsion—Etoposide—prostate cancer	8.71e-05	0.000719	CcSEcCtD
Lithium—Dehydration—Epirubicin—prostate cancer	8.71e-05	0.000718	CcSEcCtD
Lithium—Dyspepsia—Mitoxantrone—prostate cancer	8.69e-05	0.000717	CcSEcCtD
Lithium—Tinnitus—Capecitabine—prostate cancer	8.67e-05	0.000715	CcSEcCtD
Lithium—Gastrointestinal pain—Estradiol—prostate cancer	8.66e-05	0.000715	CcSEcCtD
Lithium—Dry skin—Epirubicin—prostate cancer	8.58e-05	0.000708	CcSEcCtD
Lithium—Decreased appetite—Mitoxantrone—prostate cancer	8.58e-05	0.000708	CcSEcCtD
Lithium—Arrhythmia—Docetaxel—prostate cancer	8.58e-05	0.000708	CcSEcCtD
Lithium—Fatigue—Mitoxantrone—prostate cancer	8.51e-05	0.000702	CcSEcCtD
Lithium—Vomiting—Goserelin—prostate cancer	8.49e-05	0.000701	CcSEcCtD
Lithium—Alopecia—Docetaxel—prostate cancer	8.48e-05	0.0007	CcSEcCtD
Lithium—Discomfort—Etoposide—prostate cancer	8.46e-05	0.000698	CcSEcCtD
Lithium—Bradycardia—Prednisone—prostate cancer	8.43e-05	0.000696	CcSEcCtD
Lithium—Rash—Goserelin—prostate cancer	8.42e-05	0.000695	CcSEcCtD
Lithium—Dermatitis—Goserelin—prostate cancer	8.42e-05	0.000694	CcSEcCtD
Lithium—Vomiting—Conjugated Estrogens—prostate cancer	8.41e-05	0.000694	CcSEcCtD
Lithium—Body temperature increased—Estradiol—prostate cancer	8.37e-05	0.000691	CcSEcCtD
Lithium—Abdominal pain—Estradiol—prostate cancer	8.37e-05	0.000691	CcSEcCtD
Lithium—Headache—Goserelin—prostate cancer	8.37e-05	0.000691	CcSEcCtD
Lithium—Rash—Conjugated Estrogens—prostate cancer	8.34e-05	0.000688	CcSEcCtD
Lithium—Dermatitis—Conjugated Estrogens—prostate cancer	8.34e-05	0.000688	CcSEcCtD
Lithium—Arrhythmia—Capecitabine—prostate cancer	8.3e-05	0.000685	CcSEcCtD
Lithium—Headache—Conjugated Estrogens—prostate cancer	8.29e-05	0.000684	CcSEcCtD
Lithium—Gastritis—Epirubicin—prostate cancer	8.28e-05	0.000684	CcSEcCtD
Lithium—Confusional state—Etoposide—prostate cancer	8.28e-05	0.000683	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—prostate cancer	8.26e-05	0.000681	CcSEcCtD
Lithium—Hallucination—Prednisone—prostate cancer	8.24e-05	0.00068	CcSEcCtD
Lithium—Alopecia—Capecitabine—prostate cancer	8.21e-05	0.000678	CcSEcCtD
Lithium—Dysgeusia—Docetaxel—prostate cancer	8.18e-05	0.000675	CcSEcCtD
Lithium—Ataxia—Doxorubicin—prostate cancer	8.14e-05	0.000672	CcSEcCtD
Lithium—Feeling abnormal—Mitoxantrone—prostate cancer	8.13e-05	0.000671	CcSEcCtD
Lithium—Gastrointestinal pain—Mitoxantrone—prostate cancer	8.07e-05	0.000666	CcSEcCtD
Lithium—Dehydration—Doxorubicin—prostate cancer	8.06e-05	0.000665	CcSEcCtD
Lithium—Flatulence—Capecitabine—prostate cancer	7.97e-05	0.000658	CcSEcCtD
Lithium—Dry skin—Doxorubicin—prostate cancer	7.94e-05	0.000655	CcSEcCtD
Lithium—Nausea—Goserelin—prostate cancer	7.94e-05	0.000655	CcSEcCtD
Lithium—Dysgeusia—Capecitabine—prostate cancer	7.92e-05	0.000654	CcSEcCtD
Lithium—Nausea—Conjugated Estrogens—prostate cancer	7.86e-05	0.000649	CcSEcCtD
Lithium—Anorexia—Etoposide—prostate cancer	7.82e-05	0.000646	CcSEcCtD
Lithium—Abdominal pain—Mitoxantrone—prostate cancer	7.8e-05	0.000644	CcSEcCtD
Lithium—Body temperature increased—Mitoxantrone—prostate cancer	7.8e-05	0.000644	CcSEcCtD
Lithium—Hypotension—Etoposide—prostate cancer	7.67e-05	0.000633	CcSEcCtD
Lithium—Gastritis—Doxorubicin—prostate cancer	7.67e-05	0.000632	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—prostate cancer	7.64e-05	0.00063	CcSEcCtD
Lithium—Vision blurred—Capecitabine—prostate cancer	7.63e-05	0.000629	CcSEcCtD
Lithium—Asthenia—Estradiol—prostate cancer	7.6e-05	0.000627	CcSEcCtD
Lithium—Tremor—Capecitabine—prostate cancer	7.58e-05	0.000626	CcSEcCtD
Lithium—Syncope—Docetaxel—prostate cancer	7.5e-05	0.000618	CcSEcCtD
Lithium—Arrhythmia—Prednisone—prostate cancer	7.4e-05	0.00061	CcSEcCtD
Lithium—Weight increased—Epirubicin—prostate cancer	7.36e-05	0.000608	CcSEcCtD
Lithium—Loss of consciousness—Docetaxel—prostate cancer	7.35e-05	0.000606	CcSEcCtD
Lithium—Weight decreased—Epirubicin—prostate cancer	7.32e-05	0.000604	CcSEcCtD
Lithium—Alopecia—Prednisone—prostate cancer	7.32e-05	0.000604	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—prostate cancer	7.3e-05	0.000602	CcSEcCtD
Lithium—Somnolence—Etoposide—prostate cancer	7.3e-05	0.000602	CcSEcCtD
Lithium—Vertigo—Capecitabine—prostate cancer	7.27e-05	0.0006	CcSEcCtD
Lithium—Syncope—Capecitabine—prostate cancer	7.26e-05	0.000599	CcSEcCtD
Lithium—Diarrhoea—Estradiol—prostate cancer	7.25e-05	0.000598	CcSEcCtD
Lithium—Convulsion—Docetaxel—prostate cancer	7.24e-05	0.000598	CcSEcCtD
Lithium—Drowsiness—Epirubicin—prostate cancer	7.21e-05	0.000595	CcSEcCtD
Lithium—Decreased appetite—Etoposide—prostate cancer	7.14e-05	0.000589	CcSEcCtD
Lithium—Arthralgia—Docetaxel—prostate cancer	7.12e-05	0.000587	CcSEcCtD
Lithium—Loss of consciousness—Capecitabine—prostate cancer	7.11e-05	0.000587	CcSEcCtD
Lithium—Asthenia—Mitoxantrone—prostate cancer	7.08e-05	0.000584	CcSEcCtD
Lithium—Fatigue—Etoposide—prostate cancer	7.08e-05	0.000584	CcSEcCtD
Lithium—Dizziness—Estradiol—prostate cancer	7e-05	0.000578	CcSEcCtD
Lithium—Dry mouth—Docetaxel—prostate cancer	6.96e-05	0.000574	CcSEcCtD
Lithium—Arthralgia—Capecitabine—prostate cancer	6.89e-05	0.000568	CcSEcCtD
Lithium—Confusional state—Docetaxel—prostate cancer	6.88e-05	0.000567	CcSEcCtD
Lithium—Oedema—Docetaxel—prostate cancer	6.82e-05	0.000563	CcSEcCtD
Lithium—Weight increased—Doxorubicin—prostate cancer	6.81e-05	0.000562	CcSEcCtD
Lithium—Discomfort—Capecitabine—prostate cancer	6.81e-05	0.000562	CcSEcCtD
Lithium—Vision blurred—Prednisone—prostate cancer	6.79e-05	0.00056	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—prostate cancer	6.77e-05	0.000559	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—prostate cancer	6.76e-05	0.000558	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—prostate cancer	6.75e-05	0.000557	CcSEcCtD
Lithium—Diarrhoea—Mitoxantrone—prostate cancer	6.75e-05	0.000557	CcSEcCtD
Lithium—Dry mouth—Capecitabine—prostate cancer	6.74e-05	0.000556	CcSEcCtD
Lithium—Vomiting—Estradiol—prostate cancer	6.73e-05	0.000556	CcSEcCtD
Lithium—Gastrointestinal pain—Etoposide—prostate cancer	6.71e-05	0.000554	CcSEcCtD
Lithium—Shock—Docetaxel—prostate cancer	6.71e-05	0.000554	CcSEcCtD
Lithium—Rash—Estradiol—prostate cancer	6.68e-05	0.000551	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—prostate cancer	6.67e-05	0.000551	CcSEcCtD
Lithium—Dermatitis—Estradiol—prostate cancer	6.67e-05	0.00055	CcSEcCtD
Lithium—Confusional state—Capecitabine—prostate cancer	6.66e-05	0.000549	CcSEcCtD
Lithium—Headache—Estradiol—prostate cancer	6.63e-05	0.000547	CcSEcCtD
Lithium—Agitation—Prednisone—prostate cancer	6.62e-05	0.000547	CcSEcCtD
Lithium—Oedema—Capecitabine—prostate cancer	6.6e-05	0.000545	CcSEcCtD
Lithium—Bradycardia—Epirubicin—prostate cancer	6.59e-05	0.000544	CcSEcCtD
Lithium—Angioedema—Prednisone—prostate cancer	6.59e-05	0.000543	CcSEcCtD
Lithium—Anorexia—Docetaxel—prostate cancer	6.5e-05	0.000536	CcSEcCtD
Lithium—Shock—Capecitabine—prostate cancer	6.5e-05	0.000536	CcSEcCtD
Lithium—Body temperature increased—Etoposide—prostate cancer	6.49e-05	0.000535	CcSEcCtD
Lithium—Abdominal pain—Etoposide—prostate cancer	6.49e-05	0.000535	CcSEcCtD
Lithium—Vertigo—Prednisone—prostate cancer	6.48e-05	0.000534	CcSEcCtD
Lithium—Syncope—Prednisone—prostate cancer	6.46e-05	0.000533	CcSEcCtD
Lithium—Hypotension—Docetaxel—prostate cancer	6.37e-05	0.000526	CcSEcCtD
Lithium—Loss of consciousness—Prednisone—prostate cancer	6.34e-05	0.000523	CcSEcCtD
Lithium—Anorexia—Capecitabine—prostate cancer	6.3e-05	0.000519	CcSEcCtD
Lithium—Nausea—Estradiol—prostate cancer	6.29e-05	0.000519	CcSEcCtD
Lithium—Vomiting—Mitoxantrone—prostate cancer	6.27e-05	0.000518	CcSEcCtD
Lithium—Convulsion—Prednisone—prostate cancer	6.25e-05	0.000515	CcSEcCtD
Lithium—Rash—Mitoxantrone—prostate cancer	6.22e-05	0.000513	CcSEcCtD
Lithium—Dermatitis—Mitoxantrone—prostate cancer	6.22e-05	0.000513	CcSEcCtD
Lithium—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.21e-05	0.000513	CcSEcCtD
Lithium—Headache—Mitoxantrone—prostate cancer	6.18e-05	0.00051	CcSEcCtD
Lithium—Hypotension—Capecitabine—prostate cancer	6.17e-05	0.000509	CcSEcCtD
Lithium—Arthralgia—Prednisone—prostate cancer	6.14e-05	0.000506	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—prostate cancer	6.1e-05	0.000503	CcSEcCtD
Lithium—Somnolence—Docetaxel—prostate cancer	6.06e-05	0.0005	CcSEcCtD
Lithium—Discomfort—Prednisone—prostate cancer	6.06e-05	0.0005	CcSEcCtD
Lithium—Tinnitus—Epirubicin—prostate cancer	6.04e-05	0.000498	CcSEcCtD
Lithium—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.02e-05	0.000496	CcSEcCtD
Lithium—Dyspepsia—Docetaxel—prostate cancer	6e-05	0.000495	CcSEcCtD
Lithium—Decreased appetite—Docetaxel—prostate cancer	5.93e-05	0.000489	CcSEcCtD
Lithium—Asthenia—Etoposide—prostate cancer	5.89e-05	0.000486	CcSEcCtD
Lithium—Oedema—Prednisone—prostate cancer	5.88e-05	0.000485	CcSEcCtD
Lithium—Fatigue—Docetaxel—prostate cancer	5.88e-05	0.000485	CcSEcCtD
Lithium—Nausea—Mitoxantrone—prostate cancer	5.86e-05	0.000484	CcSEcCtD
Lithium—Dyspepsia—Capecitabine—prostate cancer	5.81e-05	0.00048	CcSEcCtD
Lithium—Shock—Prednisone—prostate cancer	5.79e-05	0.000478	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—prostate cancer	5.79e-05	0.000477	CcSEcCtD
Lithium—Decreased appetite—Capecitabine—prostate cancer	5.74e-05	0.000474	CcSEcCtD
Lithium—Alopecia—Epirubicin—prostate cancer	5.72e-05	0.000472	CcSEcCtD
Lithium—Fatigue—Capecitabine—prostate cancer	5.69e-05	0.00047	CcSEcCtD
Lithium—Feeling abnormal—Docetaxel—prostate cancer	5.62e-05	0.000464	CcSEcCtD
Lithium—Diarrhoea—Etoposide—prostate cancer	5.62e-05	0.000463	CcSEcCtD
Lithium—Anorexia—Prednisone—prostate cancer	5.61e-05	0.000463	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—prostate cancer	5.59e-05	0.000461	CcSEcCtD
Lithium—Gastrointestinal pain—Docetaxel—prostate cancer	5.58e-05	0.00046	CcSEcCtD
Lithium—Flatulence—Epirubicin—prostate cancer	5.56e-05	0.000458	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—prostate cancer	5.52e-05	0.000456	CcSEcCtD
Lithium—Feeling abnormal—Capecitabine—prostate cancer	5.44e-05	0.000449	CcSEcCtD
Lithium—Dizziness—Etoposide—prostate cancer	5.43e-05	0.000448	CcSEcCtD
Lithium—Gastrointestinal pain—Capecitabine—prostate cancer	5.4e-05	0.000446	CcSEcCtD
Lithium—Body temperature increased—Docetaxel—prostate cancer	5.39e-05	0.000445	CcSEcCtD
Lithium—Abdominal pain—Docetaxel—prostate cancer	5.39e-05	0.000445	CcSEcCtD
Lithium—Musculoskeletal discomfort—Prednisone—prostate cancer	5.36e-05	0.000442	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—prostate cancer	5.35e-05	0.000442	CcSEcCtD
Lithium—Vision blurred—Epirubicin—prostate cancer	5.31e-05	0.000438	CcSEcCtD
Lithium—Alopecia—Doxorubicin—prostate cancer	5.3e-05	0.000437	CcSEcCtD
Lithium—Abdominal pain—Capecitabine—prostate cancer	5.22e-05	0.000431	CcSEcCtD
Lithium—Body temperature increased—Capecitabine—prostate cancer	5.22e-05	0.000431	CcSEcCtD
Lithium—Vomiting—Etoposide—prostate cancer	5.22e-05	0.000431	CcSEcCtD
Lithium—Agitation—Epirubicin—prostate cancer	5.18e-05	0.000427	CcSEcCtD
Lithium—Dyspepsia—Prednisone—prostate cancer	5.18e-05	0.000427	CcSEcCtD
Lithium—Rash—Etoposide—prostate cancer	5.18e-05	0.000427	CcSEcCtD
Lithium—Dermatitis—Etoposide—prostate cancer	5.17e-05	0.000427	CcSEcCtD
Lithium—Headache—Etoposide—prostate cancer	5.14e-05	0.000424	CcSEcCtD
Lithium—Flatulence—Doxorubicin—prostate cancer	5.14e-05	0.000424	CcSEcCtD
Lithium—Decreased appetite—Prednisone—prostate cancer	5.11e-05	0.000422	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—prostate cancer	5.11e-05	0.000421	CcSEcCtD
Lithium—Fatigue—Prednisone—prostate cancer	5.07e-05	0.000418	CcSEcCtD
Lithium—Vertigo—Epirubicin—prostate cancer	5.06e-05	0.000418	CcSEcCtD
Lithium—Syncope—Epirubicin—prostate cancer	5.06e-05	0.000417	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—prostate cancer	4.95e-05	0.000409	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—prostate cancer	4.92e-05	0.000406	CcSEcCtD
Lithium—Asthenia—Docetaxel—prostate cancer	4.89e-05	0.000404	CcSEcCtD
Lithium—Convulsion—Epirubicin—prostate cancer	4.88e-05	0.000403	CcSEcCtD
Lithium—Nausea—Etoposide—prostate cancer	4.88e-05	0.000402	CcSEcCtD
Lithium—Feeling abnormal—Prednisone—prostate cancer	4.85e-05	0.0004	CcSEcCtD
Lithium—Gastrointestinal pain—Prednisone—prostate cancer	4.81e-05	0.000397	CcSEcCtD
Lithium—Arthralgia—Epirubicin—prostate cancer	4.8e-05	0.000396	CcSEcCtD
Lithium—Agitation—Doxorubicin—prostate cancer	4.79e-05	0.000396	CcSEcCtD
Lithium—Discomfort—Epirubicin—prostate cancer	4.74e-05	0.000391	CcSEcCtD
Lithium—Asthenia—Capecitabine—prostate cancer	4.74e-05	0.000391	CcSEcCtD
Lithium—Dry mouth—Epirubicin—prostate cancer	4.69e-05	0.000387	CcSEcCtD
Lithium—Vertigo—Doxorubicin—prostate cancer	4.69e-05	0.000387	CcSEcCtD
Lithium—Syncope—Doxorubicin—prostate cancer	4.68e-05	0.000386	CcSEcCtD
Lithium—Diarrhoea—Docetaxel—prostate cancer	4.67e-05	0.000385	CcSEcCtD
Lithium—Body temperature increased—Prednisone—prostate cancer	4.65e-05	0.000384	CcSEcCtD
Lithium—Abdominal pain—Prednisone—prostate cancer	4.65e-05	0.000384	CcSEcCtD
Lithium—Confusional state—Epirubicin—prostate cancer	4.64e-05	0.000383	CcSEcCtD
Lithium—Oedema—Epirubicin—prostate cancer	4.6e-05	0.00038	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—prostate cancer	4.58e-05	0.000378	CcSEcCtD
Lithium—Shock—Epirubicin—prostate cancer	4.53e-05	0.000373	CcSEcCtD
Lithium—Convulsion—Doxorubicin—prostate cancer	4.52e-05	0.000373	CcSEcCtD
Lithium—Diarrhoea—Capecitabine—prostate cancer	4.52e-05	0.000373	CcSEcCtD
Lithium—Dizziness—Docetaxel—prostate cancer	4.51e-05	0.000372	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—prostate cancer	4.44e-05	0.000366	CcSEcCtD
Lithium—Discomfort—Doxorubicin—prostate cancer	4.39e-05	0.000362	CcSEcCtD
Lithium—Anorexia—Epirubicin—prostate cancer	4.39e-05	0.000362	CcSEcCtD
Lithium—Dizziness—Capecitabine—prostate cancer	4.37e-05	0.00036	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—prostate cancer	4.34e-05	0.000358	CcSEcCtD
Lithium—Vomiting—Docetaxel—prostate cancer	4.34e-05	0.000358	CcSEcCtD
Lithium—Rash—Docetaxel—prostate cancer	4.3e-05	0.000355	CcSEcCtD
Lithium—Hypotension—Epirubicin—prostate cancer	4.3e-05	0.000355	CcSEcCtD
Lithium—Dermatitis—Docetaxel—prostate cancer	4.3e-05	0.000355	CcSEcCtD
Lithium—Confusional state—Doxorubicin—prostate cancer	4.29e-05	0.000354	CcSEcCtD
Lithium—Headache—Docetaxel—prostate cancer	4.27e-05	0.000353	CcSEcCtD
Lithium—Oedema—Doxorubicin—prostate cancer	4.26e-05	0.000351	CcSEcCtD
Lithium—Asthenia—Prednisone—prostate cancer	4.22e-05	0.000348	CcSEcCtD
Lithium—Vomiting—Capecitabine—prostate cancer	4.2e-05	0.000346	CcSEcCtD
Lithium—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.19e-05	0.000346	CcSEcCtD
Lithium—Shock—Doxorubicin—prostate cancer	4.19e-05	0.000346	CcSEcCtD
Lithium—Rash—Capecitabine—prostate cancer	4.16e-05	0.000344	CcSEcCtD
Lithium—Dermatitis—Capecitabine—prostate cancer	4.16e-05	0.000343	CcSEcCtD
Lithium—Headache—Capecitabine—prostate cancer	4.14e-05	0.000341	CcSEcCtD
Lithium—Somnolence—Epirubicin—prostate cancer	4.09e-05	0.000337	CcSEcCtD
Lithium—Anorexia—Doxorubicin—prostate cancer	4.06e-05	0.000335	CcSEcCtD
Lithium—Nausea—Docetaxel—prostate cancer	4.05e-05	0.000334	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—prostate cancer	4.05e-05	0.000334	CcSEcCtD
Lithium—Diarrhoea—Prednisone—prostate cancer	4.03e-05	0.000332	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—prostate cancer	4e-05	0.00033	CcSEcCtD
Lithium—Hypotension—Doxorubicin—prostate cancer	3.98e-05	0.000328	CcSEcCtD
Lithium—Fatigue—Epirubicin—prostate cancer	3.97e-05	0.000327	CcSEcCtD
Lithium—Nausea—Capecitabine—prostate cancer	3.92e-05	0.000324	CcSEcCtD
Lithium—Dizziness—Prednisone—prostate cancer	3.89e-05	0.000321	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.88e-05	0.00032	CcSEcCtD
Lithium—Feeling abnormal—Epirubicin—prostate cancer	3.79e-05	0.000313	CcSEcCtD
Lithium—Somnolence—Doxorubicin—prostate cancer	3.78e-05	0.000312	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—prostate cancer	3.76e-05	0.00031	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—prostate cancer	3.75e-05	0.000309	CcSEcCtD
Lithium—Vomiting—Prednisone—prostate cancer	3.74e-05	0.000309	CcSEcCtD
Lithium—Rash—Prednisone—prostate cancer	3.71e-05	0.000306	CcSEcCtD
Lithium—Dermatitis—Prednisone—prostate cancer	3.71e-05	0.000306	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—prostate cancer	3.7e-05	0.000305	CcSEcCtD
Lithium—Headache—Prednisone—prostate cancer	3.69e-05	0.000304	CcSEcCtD
Lithium—Fatigue—Doxorubicin—prostate cancer	3.67e-05	0.000303	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—prostate cancer	3.64e-05	0.0003	CcSEcCtD
Lithium—Body temperature increased—Epirubicin—prostate cancer	3.64e-05	0.0003	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—prostate cancer	3.51e-05	0.000289	CcSEcCtD
Lithium—Nausea—Prednisone—prostate cancer	3.49e-05	0.000288	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—prostate cancer	3.48e-05	0.000287	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—prostate cancer	3.37e-05	0.000278	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—prostate cancer	3.37e-05	0.000278	CcSEcCtD
Lithium—Asthenia—Epirubicin—prostate cancer	3.3e-05	0.000272	CcSEcCtD
Lithium—Diarrhoea—Epirubicin—prostate cancer	3.15e-05	0.00026	CcSEcCtD
Lithium—Asthenia—Doxorubicin—prostate cancer	3.05e-05	0.000252	CcSEcCtD
Lithium—Dizziness—Epirubicin—prostate cancer	3.04e-05	0.000251	CcSEcCtD
Lithium—Vomiting—Epirubicin—prostate cancer	2.93e-05	0.000241	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—prostate cancer	2.91e-05	0.00024	CcSEcCtD
Lithium—Rash—Epirubicin—prostate cancer	2.9e-05	0.000239	CcSEcCtD
Lithium—Dermatitis—Epirubicin—prostate cancer	2.9e-05	0.000239	CcSEcCtD
Lithium—Headache—Epirubicin—prostate cancer	2.88e-05	0.000238	CcSEcCtD
Lithium—Dizziness—Doxorubicin—prostate cancer	2.82e-05	0.000232	CcSEcCtD
Lithium—Nausea—Epirubicin—prostate cancer	2.73e-05	0.000225	CcSEcCtD
Lithium—Vomiting—Doxorubicin—prostate cancer	2.71e-05	0.000223	CcSEcCtD
Lithium—Rash—Doxorubicin—prostate cancer	2.68e-05	0.000221	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—prostate cancer	2.68e-05	0.000221	CcSEcCtD
Lithium—Headache—Doxorubicin—prostate cancer	2.67e-05	0.00022	CcSEcCtD
Lithium—Nausea—Doxorubicin—prostate cancer	2.53e-05	0.000209	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—LPL—prostate cancer	8.48e-06	4.76e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—STAT3—prostate cancer	8.44e-06	4.73e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL12—prostate cancer	8.42e-06	4.73e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—prostate cancer	8.42e-06	4.72e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDGFRB—prostate cancer	8.4e-06	4.71e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB3—prostate cancer	8.38e-06	4.7e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—FGFR2—prostate cancer	8.37e-06	4.7e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1A—prostate cancer	8.35e-06	4.69e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2L1—prostate cancer	8.35e-06	4.69e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—FGF2—prostate cancer	8.35e-06	4.68e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTEN—prostate cancer	8.33e-06	4.68e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—prostate cancer	8.32e-06	4.67e-05	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—prostate cancer	8.26e-06	4.63e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ITGB3—prostate cancer	8.19e-06	4.59e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MAP2K1—prostate cancer	8.11e-06	4.55e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MTHFR—prostate cancer	8.06e-06	4.52e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CD—prostate cancer	8.05e-06	4.52e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—prostate cancer	8.03e-06	4.51e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1A—prostate cancer	8.02e-06	4.5e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—JAK2—prostate cancer	8e-06	4.49e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTEN—prostate cancer	8e-06	4.49e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—SERPINE1—prostate cancer	7.96e-06	4.47e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR4—prostate cancer	7.96e-06	4.46e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PIK3CA—prostate cancer	7.96e-06	4.46e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EP300—prostate cancer	7.95e-06	4.46e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB3—prostate cancer	7.94e-06	4.46e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP9—prostate cancer	7.93e-06	4.45e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGFR2—prostate cancer	7.93e-06	4.45e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—BCL2—prostate cancer	7.93e-06	4.45e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TGFB1—prostate cancer	7.82e-06	4.39e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—MDM2—prostate cancer	7.81e-06	4.38e-05	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—prostate cancer	7.78e-06	4.36e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—prostate cancer	7.76e-06	4.35e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—SRC—prostate cancer	7.73e-06	4.34e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—FGF2—prostate cancer	7.71e-06	4.33e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—prostate cancer	7.7e-06	4.32e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PRKCQ—prostate cancer	7.69e-06	4.31e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NGFR—prostate cancer	7.69e-06	4.31e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HIF1A—prostate cancer	7.68e-06	4.31e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—prostate cancer	7.67e-06	4.3e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PIK3CA—prostate cancer	7.64e-06	4.29e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—ICAM1—prostate cancer	7.63e-06	4.28e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—prostate cancer	7.61e-06	4.27e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS3—prostate cancer	7.6e-06	4.27e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CB—prostate cancer	7.6e-06	4.26e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAP3K7—prostate cancer	7.59e-06	4.26e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—BAD—prostate cancer	7.57e-06	4.25e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CAV1—prostate cancer	7.43e-06	4.17e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—SRC—prostate cancer	7.42e-06	4.16e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—JAK2—prostate cancer	7.39e-06	4.15e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGF10—prostate cancer	7.3e-06	4.1e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HIF1A—prostate cancer	7.28e-06	4.08e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGF—prostate cancer	7.25e-06	4.07e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IRS1—prostate cancer	7.25e-06	4.07e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—prostate cancer	7.25e-06	4.07e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADRB2—prostate cancer	7.23e-06	4.05e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MDM2—prostate cancer	7.21e-06	4.05e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1B—prostate cancer	7.13e-06	4e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—prostate cancer	7.11e-06	3.99e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—LEP—prostate cancer	7.11e-06	3.99e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VAV3—prostate cancer	7.05e-06	3.95e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—prostate cancer	7.05e-06	3.95e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CAV1—prostate cancer	7.04e-06	3.95e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CB—prostate cancer	7.02e-06	3.94e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—BAD—prostate cancer	6.99e-06	3.92e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—prostate cancer	6.98e-06	3.92e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KDR—prostate cancer	6.96e-06	3.91e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—prostate cancer	6.95e-06	3.9e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFBR2—prostate cancer	6.95e-06	3.9e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ITPR1—prostate cancer	6.83e-06	3.83e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CREBBP—prostate cancer	6.8e-06	3.81e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ESR1—prostate cancer	6.79e-06	3.81e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—prostate cancer	6.77e-06	3.8e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APC—prostate cancer	6.77e-06	3.8e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDH1—prostate cancer	6.75e-06	3.78e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—prostate cancer	6.74e-06	3.78e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IRS1—prostate cancer	6.69e-06	3.75e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGF—prostate cancer	6.69e-06	3.75e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BAD—prostate cancer	6.62e-06	3.72e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1B—prostate cancer	6.59e-06	3.7e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1A—prostate cancer	6.58e-06	3.69e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—prostate cancer	6.57e-06	3.69e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1R—prostate cancer	6.54e-06	3.67e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—prostate cancer	6.5e-06	3.65e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—prostate cancer	6.5e-06	3.65e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAP2K1—prostate cancer	6.49e-06	3.64e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CD—prostate cancer	6.44e-06	3.62e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CG—prostate cancer	6.41e-06	3.6e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APC—prostate cancer	6.41e-06	3.6e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—INS—prostate cancer	6.41e-06	3.59e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—prostate cancer	6.4e-06	3.59e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGF—prostate cancer	6.34e-06	3.56e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IRS1—prostate cancer	6.34e-06	3.56e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CREBBP—prostate cancer	6.28e-06	3.52e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LPL—prostate cancer	6.27e-06	3.52e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EP300—prostate cancer	6.26e-06	3.51e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—prostate cancer	6.24e-06	3.5e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—prostate cancer	6.22e-06	3.49e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFRB—prostate cancer	6.21e-06	3.48e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—FGF2—prostate cancer	6.17e-06	3.46e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GSK3B—prostate cancer	6.15e-06	3.45e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—prostate cancer	6.15e-06	3.45e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—SRC—prostate cancer	6.09e-06	3.42e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1A—prostate cancer	6.08e-06	3.41e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—INS—prostate cancer	6.07e-06	3.41e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—prostate cancer	6.06e-06	3.4e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ITGB3—prostate cancer	6.05e-06	3.39e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAP2K1—prostate cancer	5.99e-06	3.36e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CD—prostate cancer	5.95e-06	3.34e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CREBBP—prostate cancer	5.95e-06	3.34e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—JAK2—prostate cancer	5.91e-06	3.32e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—prostate cancer	5.89e-06	3.31e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SERPINE1—prostate cancer	5.88e-06	3.3e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3CA—prostate cancer	5.88e-06	3.3e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—prostate cancer	5.87e-06	3.3e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1—prostate cancer	5.87e-06	3.29e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB3—prostate cancer	5.87e-06	3.29e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGFR2—prostate cancer	5.86e-06	3.29e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2—prostate cancer	5.86e-06	3.29e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EP300—prostate cancer	5.78e-06	3.24e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MDM2—prostate cancer	5.77e-06	3.24e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—FGF2—prostate cancer	5.7e-06	3.2e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—prostate cancer	5.69e-06	3.19e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAP2K1—prostate cancer	5.68e-06	3.18e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3CA—prostate cancer	5.65e-06	3.17e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CD—prostate cancer	5.64e-06	3.16e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—prostate cancer	5.63e-06	3.16e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—SRC—prostate cancer	5.62e-06	3.16e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS3—prostate cancer	5.62e-06	3.15e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CB—prostate cancer	5.62e-06	3.15e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SERPINE1—prostate cancer	5.58e-06	3.13e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—JAK2—prostate cancer	5.46e-06	3.06e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—prostate cancer	5.44e-06	3.05e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—prostate cancer	5.42e-06	3.04e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGF2—prostate cancer	5.4e-06	3.03e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HIF1A—prostate cancer	5.38e-06	3.02e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—prostate cancer	5.34e-06	3e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MDM2—prostate cancer	5.33e-06	2.99e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOS3—prostate cancer	5.32e-06	2.99e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1B—prostate cancer	5.27e-06	2.96e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—prostate cancer	5.26e-06	2.95e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LEP—prostate cancer	5.25e-06	2.95e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—prostate cancer	5.21e-06	2.92e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CAV1—prostate cancer	5.2e-06	2.92e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CB—prostate cancer	5.19e-06	2.91e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JAK2—prostate cancer	5.17e-06	2.9e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—prostate cancer	5.16e-06	2.89e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KDR—prostate cancer	5.15e-06	2.89e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—prostate cancer	5.14e-06	2.88e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MDM2—prostate cancer	5.05e-06	2.83e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—prostate cancer	5.04e-06	2.83e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—prostate cancer	5.04e-06	2.83e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—prostate cancer	5.03e-06	2.82e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ESR1—prostate cancer	5.01e-06	2.81e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—prostate cancer	4.98e-06	2.79e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—prostate cancer	4.98e-06	2.79e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—prostate cancer	4.93e-06	2.77e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CB—prostate cancer	4.91e-06	2.76e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BAD—prostate cancer	4.89e-06	2.75e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1B—prostate cancer	4.87e-06	2.73e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1A—prostate cancer	4.86e-06	2.73e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—prostate cancer	4.85e-06	2.72e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—prostate cancer	4.8e-06	2.69e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CG—prostate cancer	4.74e-06	2.66e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APC—prostate cancer	4.74e-06	2.66e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—prostate cancer	4.72e-06	2.65e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGF—prostate cancer	4.69e-06	2.63e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IRS1—prostate cancer	4.69e-06	2.63e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—prostate cancer	4.66e-06	2.61e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3CA—prostate cancer	4.63e-06	2.6e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EP300—prostate cancer	4.63e-06	2.6e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1B—prostate cancer	4.61e-06	2.59e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—prostate cancer	4.61e-06	2.59e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—prostate cancer	4.6e-06	2.58e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—prostate cancer	4.52e-06	2.54e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—prostate cancer	4.51e-06	2.53e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—SRC—prostate cancer	4.5e-06	2.53e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1A—prostate cancer	4.49e-06	2.52e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—INS—prostate cancer	4.49e-06	2.52e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—prostate cancer	4.48e-06	2.51e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—prostate cancer	4.4e-06	2.47e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CREBBP—prostate cancer	4.39e-06	2.47e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—prostate cancer	4.36e-06	2.44e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—prostate cancer	4.34e-06	2.44e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1—prostate cancer	4.34e-06	2.43e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3CA—prostate cancer	4.28e-06	2.4e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EP300—prostate cancer	4.27e-06	2.4e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—prostate cancer	4.27e-06	2.4e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1A—prostate cancer	4.26e-06	2.39e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—prostate cancer	4.25e-06	2.38e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAP2K1—prostate cancer	4.19e-06	2.35e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CD—prostate cancer	4.17e-06	2.34e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SRC—prostate cancer	4.16e-06	2.33e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SERPINE1—prostate cancer	4.12e-06	2.31e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—prostate cancer	4.1e-06	2.3e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EP300—prostate cancer	4.05e-06	2.27e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—prostate cancer	4.01e-06	2.25e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGF2—prostate cancer	3.99e-06	2.24e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—prostate cancer	3.95e-06	2.21e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SRC—prostate cancer	3.94e-06	2.21e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOS3—prostate cancer	3.93e-06	2.21e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—prostate cancer	3.84e-06	2.15e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JAK2—prostate cancer	3.82e-06	2.15e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—prostate cancer	3.8e-06	2.13e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—prostate cancer	3.79e-06	2.13e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—prostate cancer	3.79e-06	2.12e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MDM2—prostate cancer	3.73e-06	2.09e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—prostate cancer	3.73e-06	2.09e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—prostate cancer	3.72e-06	2.09e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—prostate cancer	3.72e-06	2.08e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—prostate cancer	3.68e-06	2.06e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—prostate cancer	3.64e-06	2.04e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CB—prostate cancer	3.63e-06	2.04e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—prostate cancer	3.53e-06	1.98e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—prostate cancer	3.52e-06	1.98e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—prostate cancer	3.5e-06	1.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—prostate cancer	3.49e-06	1.96e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—prostate cancer	3.45e-06	1.94e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—prostate cancer	3.44e-06	1.93e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3CA—prostate cancer	3.42e-06	1.92e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1B—prostate cancer	3.41e-06	1.91e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—prostate cancer	3.34e-06	1.87e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—prostate cancer	3.34e-06	1.87e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—prostate cancer	3.26e-06	1.83e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—prostate cancer	3.25e-06	1.82e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—prostate cancer	3.22e-06	1.81e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3CA—prostate cancer	3.16e-06	1.77e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—prostate cancer	3.16e-06	1.77e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1A—prostate cancer	3.15e-06	1.76e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—prostate cancer	3.14e-06	1.76e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—prostate cancer	3.03e-06	1.7e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CA—prostate cancer	3e-06	1.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EP300—prostate cancer	2.99e-06	1.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SRC—prostate cancer	2.91e-06	1.63e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—prostate cancer	2.9e-06	1.63e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—prostate cancer	2.83e-06	1.59e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—prostate cancer	2.81e-06	1.57e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—prostate cancer	2.8e-06	1.57e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—prostate cancer	2.8e-06	1.57e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—prostate cancer	2.65e-06	1.49e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—prostate cancer	2.61e-06	1.46e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—prostate cancer	2.6e-06	1.46e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—prostate cancer	2.58e-06	1.45e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—prostate cancer	2.55e-06	1.43e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—prostate cancer	2.45e-06	1.37e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—prostate cancer	2.41e-06	1.35e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CA—prostate cancer	2.21e-06	1.24e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—prostate cancer	2.14e-06	1.2e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—prostate cancer	1.96e-06	1.1e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—prostate cancer	1.81e-06	1.01e-05	CbGpPWpGaD
